NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysesMontserrat García‐Closas, Nathaniel Rothman, Adonina Tardón et al.|The Lancet|2005Cited by 631
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with OutcomeYves Allory, Francisco X. Real, Willemien Beukers et al.|European Urology|2013Cited by 289
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent eventsLaia Agell, Josep Lloreta|Modern Pathology|2010Cited by 51